Clinical Trials Logo

Filter by:
NCT ID: NCT04603287 Recruiting - Clinical trials for Locally Advanced or Metastatic Epithelial Tumor

A Study of SI-B001, an EGFR/HER3 Bispecific Antibody, in Locally Advanced or Metastatic Epithelial Tumors

Start date: April 17, 2020
Phase: Phase 1
Study type: Interventional

In phase Ia study, the safety and tolerability of SI-B001 in patients with locally advanced or metastatic epithelial malignancies will be investigated to determine the dose-limiting toxicity (DLT), maximum tolerated dose (MTD) of SI-B001. In the phase Ib study, the safety and tolerability of SI-B001 at the phase Ia recommended dose will be further investigated, and recommended phase II dose (RP2D) for phase II clinical studies will be determined. In addition, the preliminary efficacy, pharmacokinetic characteristics, and immunogenicity of SI-B001 in patients with locally advanced or metastatic epithelial tumors will be evaluated.

NCT ID: NCT04733430 Recruiting - Lung Cancer Clinical Trials

LALUCA Research Platform A Prospective Analysis of Lung Cancer Diagnosis and Management in Clinical Practice

LALUCA
Start date: April 17, 2020
Phase:
Study type: Observational [Patient Registry]

This is a prospective analysis of the diagnosis and treatment of lung cancer in a real-world setting. The aim of the project is to establish a clinical platform to collect representative data on molecular testing, sequence of systemic tumor therapy and other therapies, and disease progression of patients with lung cancer. A special focus will be on molecular biomarker testing and reflex NGS testing. Another aim of the registry is the collection of quality indicators in lung cancer care. The results of the register will be used to describe the current state of care and to develop it further for the future.

NCT ID: NCT04787185 Recruiting - Clinical trials for Brain Metastases From NSCLC

Stereotactic Radiotherapy in Association With Immunotherapy for the Treatment of NSCLC Brain Metastases

STRAITLUC
Start date: April 17, 2020
Phase:
Study type: Observational

The study's primary objective is the evaluation of toxicities reported during RS or HFSRT in patients with brain metastases from NSCLC undergoing immunotherapy (Safety), with particular reference to the rate of symptomatic radionecrosis and intralesional hemorrhage. Others primary objectives of the study are the Feasibility and the intracranial control of the disease, both local (site radiotherapy treatment) and at a distance (intracranial, but at a distance from the site of the disease treated with stereotaxic radiotherapy). The secondary objectives concern quality assessment of life of the patients under study (Quality Of Life, QoL).

NCT ID: NCT03826693 Recruiting - Clinical trials for Obsessive-Compulsive Disorder

Efficacy of Nitrous Oxide in OCD: Pilot Study

Start date: April 17, 2021
Phase: Phase 2
Study type: Interventional

This study investigates whether the commonly used and well-tolerated inhaled anesthetic nitrous oxide can rapidly improve symptoms of OCD.

NCT ID: NCT04832776 Recruiting - Clinical trials for Liver Metastasis Colon Cancer

FOLFOXIRI Plus Cetuximab Versus FOLFOXIRI Plus Bevacizumab in Conversion Therapy of Right-sided Colon Cancer Liver Metastases

Start date: April 17, 2021
Phase: Phase 2
Study type: Interventional

To compare the efficacy of FOLFOXIRI plus Cetuximab and FOLFOXIRI plus Bevacuzumab in the conversion therapy of right-sided colon cancer liver metastases

NCT ID: NCT04860154 Recruiting - Clinical trials for Cholangiocarcinoma Non-resectable

Photodynamic Therapy for Cholangiocarcinoma

Start date: April 17, 2021
Phase: N/A
Study type: Interventional

Comparison of the bile duct patency with photodynamic therapy (PDT) and regular Endoscopic Retrograde Cholangiopancreatography(ERCP) stents in unresectable cholangiocarcinoma.

NCT ID: NCT04922242 Recruiting - Premature Birth Clinical Trials

Welch Emotional Connection Screen (WECS) in the NICU

Start date: April 17, 2021
Phase: N/A
Study type: Interventional

The purpose of this study is to assess knowledge about emotional connection, attitude about relational health, and efficacy of Welch Emotional Connection Screen (WECS) training in the NICU. The investigators seek to discern if through this didactic training, frontline NICU clinicians can be taught to reliably use the WECS to rate parent-child relational health. Additionally, the investigators seek to learn if there is construct and theoretical validity of the hospitalized infant preterm WECS by correlating WECS scores to physiological, behavioral and mental health markers for parent and infant.

NCT ID: NCT05242666 Recruiting - Clinical trials for Cervical Spondylosis With Myelopathy

Quantiative MRI and Myelin-PET for the Assessment of Degenerative Cervical Myelopathy

IMAGE-DCM
Start date: April 17, 2021
Phase: N/A
Study type: Interventional

To use advanced imaging techniques, including MRI Brain and Spinal Cord, and MRI/PET Spinal Cord to provide an assessment of Degenerative Cervical Myelopathy to improve understanding of the pathophysiology and natural history of DCM.

NCT ID: NCT05259384 Recruiting - Pancreatic Neoplasm Clinical Trials

Robotic Versus Laparoscopic Surgery for Patients With Pancreatic Cystic Neoplasms

Start date: April 17, 2021
Phase: N/A
Study type: Interventional

Pancreatic cystic neoplasm (PCN) is a type of neoplastic lesion formed by the proliferation of pancreatic duct or acinar epithelial cells and retention of pancreatic secretions. The tumor can be located in the head and neck of the pancreas or the body and tail of the pancreas. Conventionally, open pancreaticoduodenectomy or open distal pancreatectomy was performed for patients with PCN locates either at the head or tail. In the ear of minimally invasive pancreatic surgery, when compared with open surgery, laparoscopic technology or Da Vinci robotic technology can avoid some open procedures limitations. Here we design this prospective randomized clinical trial to compare robotic surgery to laparoscopic surgery for the treatment of PCN and verify the safety and feasibility of both two minimally invasive procedures.

NCT ID: NCT05221229 Recruiting - Atrial Fibrillation Clinical Trials

Outcome of Overweight AF Patients Following Ablation With a Potential Weight Loss Medication ( GOAL-AF )

GOAL-AF
Start date: April 17, 2022
Phase:
Study type: Observational

Atrial Fibrillation (AF) is the most common abnormal heart rhythm(arrhythmia) affecting about one in 40 people in England. Patients with AF often have symptoms ranging from palpitations and breathlessness, and a small number of patients may develop heart failure. The major complication of AF is stroke, and this is effectively treated with blood thinning medications (anticoagulation). AF symptoms can lead to significant decline in quality of life and can affect patients' ability to work and exercise. There are numerous treatments targeted at maintaining normal rhythm and preventing AF recurrence. These include medications and catheter ablation. Ablation has been shown to be more effective than medications for the long-term control of AF, but its efficacy is significantly reduced by upstream conditions such as high blood pressure, obesity, diabetes, and poor fitness levels. This results in increased complications, repeat procedures, and increased AF recurrence or patients. Research currently available has shown that intensive risk factor control with weight loss and increased fitness can reduce AF burden and improve results from ablation. However, achieving these targets outside of a clinical trial have been challenging. Recent data has shown that a new class of drug (Liraglutide) can result in significant weight loss over a 3-month period, and pre-treatment prior to liver transplant has improved results and patient recovery. The overall aim of this study is to determine if accelerated weight loss by Liraglutide before AF ablation is feasible to base a future trial to inform if this approach improves outcomes and can be safely adopted into routine clinical practice.